Literature DB >> 11444773

Lymphocyte recognition of human parvovirus B19 non-structural (NS1) protein: associations with occurrence of acute and chronic arthropathy?

Leslie Ann Mitchell1, Roger Leong1, Karla A Rosenke1.   

Abstract

Immune recognition of recombinant parvovirus B19 non-structural (rNS1) protein was studied by immunoblot and lymphoproliferative assays in blood from the following B19 seropositive groups: B19 infected (n = 14), B19 exposed but non-infected (n = 16), other illness with rash (n = 3), chronic arthropathy of unknown aetiology (n = 4) and healthy controls (n = 7). Sera from 11 B19 seronegative subjects were also studied. Sera collected at initial diagnosis or at the time of accidental B19 exposure in pregnancy were tested for NS1 antibody and evidence of B19 DNA by nested PCR. Follow-up specimens were obtained 3-12 months later for serological, PCR and proliferation studies. B19 DNA was detected sporadically in early specimens and in one follow-up specimen from a subject who developed chronic arthropathy after B19 infection. There was no correlation with development of arthropathy. NS1-specific IgG was detected in early sera from B19-infected and exposed subjects but to a lesser degree in follow-up specimens, and in only one healthy control serum. No correlation with the presence of NS1-specific antibodies was found with development of acute or chronic arthropathy. Although lymphocyte proliferation in response to stimulation with rNS1 in vitro occurred at a higher frequency in patients who developed acute and chronic joint manifestations after B19 infection, suggesting an association with this outcome, NS1-reactive lymphocytes were also found in three B19 seronegative patients, two of whom had recently been exposed to B19 but had no illness. Hence, immune recognition of NS1 may be more indicative of recent infection with, or exposure to, parvovirus B19 than associated with development of arthropathy as previously reported.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444773     DOI: 10.1099/0022-1317-50-7-627

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  7 in total

1.  T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity.

Authors:  R Franssila; J Auramo; S Modrow; M Möbs; C Oker-Blom; P Käpylä; M Söderlund-Venermo; K Hedman
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

2.  Long term follow up of serostatus after maternofetal parvovirus B19 infection.

Authors:  J Dembinski; A M Eis-Hübinger; J Maar; R Schild; P Bartmann
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

Review 3.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

4.  Increased expression and secretion of interleukin-6 in human parvovirus B19 non-structural protein (NS1) transfected COS-7 epithelial cells.

Authors:  T-C Hsu; B-S Tzang; C-N Huang; Y-J Lee; G-Y Liu; M-C Chen; G J Tsay
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

5.  Tracking of peptide-specific CD4+ T-cell responses after an acute resolving viral infection: a study of parvovirus B19.

Authors:  Victoria Kasprowicz; Adiba Isa; Thomas Tolfvenstam; Katie Jeffery; Paul Bowness; Paul Klenerman
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

6.  Parvovirus B19 nonstructural protein-induced damage of cellular DNA and resultant apoptosis.

Authors:  Brian D Poole; Violetta Kivovich; Leona Gilbert; Stanley J Naides
Journal:  Int J Med Sci       Date:  2011-01-15       Impact factor: 3.738

7.  NS1 specific CD8+ T-cells with effector function and TRBV11 dominance in a patient with parvovirus B19 associated inflammatory cardiomyopathy.

Authors:  Mathias Streitz; Michel Noutsias; Rudolf Volkmer; Maria Rohde; Gordon Brestrich; Andrea Block; Katrin Klippert; Katja Kotsch; Bernhard Ay; Michael Hummel; Uwe Kühl; Dirk Lassner; Heinz-Peter Schultheiss; Hans-Dieter Volk; Florian Kern
Journal:  PLoS One       Date:  2008-06-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.